HLS Therapeutics (TSE:HLS) Stock Price Up 0.5% – Here’s What Happened

HLS Therapeutics Inc. (TSE:HLS) shares traded up 0.5% on Thursday. The company traded as high as C$4.15 and last traded at C$4.15. Approximately 7,100 shares were traded during trading, a decline of 80% from the average daily volume of 35,203 shares. The stock had previously closed at C$4.13.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on HLS shares. Canaccord Genuity Group upgraded shares of HLS Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 13th. Raymond James Financial raised shares of HLS Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their price target for the company from C$7.00 to C$8.00 in a research note on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company. Based on data from MarketBeat.com, HLS Therapeutics currently has a consensus rating of “Strong Buy” and a consensus target price of C$8.00.

HLS Therapeutics Price Performance

The company has a fifty day simple moving average of C$3.94 and a 200 day simple moving average of C$4.23. The stock has a market capitalization of C$128.38 million, a price-to-earnings ratio of -15.37 and a beta of -0.50. The company has a debt-to-equity ratio of 75.86, a quick ratio of 1.01 and a current ratio of 1.05.

HLS Therapeutics (TSE:HLS) last issued its quarterly earnings results on Wednesday, August 12th. The company reported C($0.03) earnings per share for the quarter. The company had revenue of C$14.67 million during the quarter. HLS Therapeutics had a negative net margin of 15.26% and a negative return on equity of 14.39%. During the same period last year, the firm posted ($0.09) earnings per share. Equities research analysts forecast that HLS Therapeutics Inc. will post -0.12 EPS for the current fiscal year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.